Buprenorphine dialysis managed cross skin treatment system, including an automatic adhesive layer structure containing butylene, including (a) a waterproof support layer of buprenorphine and (b) a pressure sensitive adhesive layer, on which buprenorphine is installed Buprenorphine, the adhesive includes: (a) at least one adhesive sensitive to polymerizing pressure, (b) an effective buprenorphine basic analgesic or a pharmaceutically acceptable salt,c) a substance that increases the viscosity in an amount of about 0.1% to about 8% said pressure sensitive adhesive layer containing buprenorphine, and d) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, acid linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient for said analgesically effective amount of buprenorphine to be solubilized therein to form a mixture including said substance that increases viscosity and where the mixture containing carboxylic acid-,Buprenorphine - and substances that increase viscosity are deposition substances dispersed in pressure-sensitive adhesives, among which the pressure-sensitive adhesives containing buprenorphine are strains in contact with skin. Claim 17: according to any one of claims 1 to 16, buprenorphine is based on buprenorphine, which is a levulinic acid,The adhesive is based on poly siliques, which contains about 1% to 4% soluble PVC. Claim 46: any transdermal treatment system of claims 1 to 45 wherein a pressure-sensitive adhesive containing buprenorphine group comprises a specific antioxidant consisting of ascolbilo palmitate, bacon and ester, anthrax acid, Butylhydroxytoluene butylhydroxy or propyl galacticSistema terapéutico transdérmico para la administración transdérmica de buprenorfina, comprendiendo una estructura de capa auto-adhesiva conteniendo buprenerfina comprendiendo A) una capa de respaldo impermeable a la buprenorfina, y B) una capa adhesiva sensible a la presión conteniendo buprenorfina sobre dicha capa
